IL310210A - Methods for inhibiting the progression of oxidative retinal diseases - Google Patents

Methods for inhibiting the progression of oxidative retinal diseases

Info

Publication number
IL310210A
IL310210A IL310210A IL31021024A IL310210A IL 310210 A IL310210 A IL 310210A IL 310210 A IL310210 A IL 310210A IL 31021024 A IL31021024 A IL 31021024A IL 310210 A IL310210 A IL 310210A
Authority
IL
Israel
Prior art keywords
progression
delay
methods
retinal diseases
oxidative retinal
Prior art date
Application number
IL310210A
Other languages
English (en)
Hebrew (he)
Inventor
Karsten Schmidt
Mikhail Shchepinov
Original Assignee
Biojiva Llc
Karsten Schmidt
Mikhail Shchepinov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biojiva Llc, Karsten Schmidt, Mikhail Shchepinov filed Critical Biojiva Llc
Publication of IL310210A publication Critical patent/IL310210A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL310210A 2021-07-22 2022-07-22 Methods for inhibiting the progression of oxidative retinal diseases IL310210A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163224679P 2021-07-22 2021-07-22
US202163224690P 2021-07-22 2021-07-22
US202163224674P 2021-07-22 2021-07-22
PCT/US2022/038072 WO2023004151A1 (en) 2021-07-22 2022-07-22 Methods for inhibiting the progression of oxidative retinal diseases

Publications (1)

Publication Number Publication Date
IL310210A true IL310210A (en) 2024-03-01

Family

ID=84979648

Family Applications (1)

Application Number Title Priority Date Filing Date
IL310210A IL310210A (en) 2021-07-22 2022-07-22 Methods for inhibiting the progression of oxidative retinal diseases

Country Status (8)

Country Link
US (1) US20250099415A1 (cg-RX-API-DMAC7.html)
EP (1) EP4373479A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024526939A (cg-RX-API-DMAC7.html)
KR (1) KR20240036651A (cg-RX-API-DMAC7.html)
AU (1) AU2022313207A1 (cg-RX-API-DMAC7.html)
CA (2) CA3227139A1 (cg-RX-API-DMAC7.html)
IL (1) IL310210A (cg-RX-API-DMAC7.html)
WO (1) WO2023004151A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240091187A1 (en) * 2022-09-02 2024-03-21 Biojiva Llc Pharmaceutical compositions of d10-docosahexaenoic acid or esters thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270739A1 (en) * 2005-04-28 2006-11-30 Trustees Of Tufts College Synergistic effects of docosahexaenoic acid (DHA) and carotenoid absorption on macular pigmentation
US20100303887A1 (en) * 2007-07-30 2010-12-02 Bazan Nicolas G DHA and PEDF, a Therapeutic Composition for Nerve and Retinal Pigment Epithelial Cells
EP2219638A2 (en) * 2007-10-29 2010-08-25 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Lipoxin a4 protection for retinal cells
US10058522B2 (en) * 2011-04-26 2018-08-28 Retrotope, Inc. Oxidative retinal diseases
WO2017091279A1 (en) * 2015-11-23 2017-06-01 Retrotope, Inc. Site-specific isotopic labeling of 1, 4-diene systems
WO2020102596A1 (en) * 2018-11-15 2020-05-22 Retrotope, Inc. Deuterated compounds, compositions, and uses

Also Published As

Publication number Publication date
KR20240036651A (ko) 2024-03-20
CA3311344A1 (en) 2026-06-21
AU2022313207A1 (en) 2024-02-29
US20250099415A1 (en) 2025-03-27
WO2023004151A1 (en) 2023-01-26
JP2024526939A (ja) 2024-07-19
EP4373479A1 (en) 2024-05-29
EP4373479A4 (en) 2025-11-05
CA3227139A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
IL280710A (en) Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy
IL283372A (en) Use of cannabinoids in the treatment of epilepsy
IL262608A (en) Combination treatment of ocular inflammatory disorders and diseases
IL276383B1 (en) Treatment of ophthalmological diseases
IL261809A (en) Treatment of inflammatory diseases with inhibitors of c5a activity
HUE059638T2 (hu) Ízületi gyulladásos betegségek kombinált kezelése
EP3419633A4 (en) TREATMENT OF ALLERGIC EYE DISEASES WITH CYCLODEXTRINS
LT4331584T (lt) Lanifibranoro deuterintų darinių terapietiniai naudojimai
PL3405215T3 (pl) Sposoby leczenia choroby danona i innych zaburzeń autofagii
IL283069A (en) Methods for administering corticosteroids
IL229017B (en) Oxidative retinal diseases
EP3823646A4 (en) MITOCHONDRIAL AUGMENTATION THERAPY OF BRAIN DISEASES
EP3606535A4 (en) TREATMENT OF INFLAMMATORY INTESTINAL DISEASES WITH 2'-FUCOSYLLACTOSE COMPOUNDS
EP3737363A4 (en) METHODS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES
IL268720A (en) Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases
EP3866795A4 (en) TREATMENT OF NEUROLOGICAL DISEASES
EA201992389A1 (ru) Замещенные n-арилэтил-2-аминохинолин-4-карбоксамиды и их применение
EP4100002A4 (en) TREATMENT OF NEUROLOGICAL DISORDERS WITH AVERMECTINS
IL270900A (en) Treatment of cutaneous disorders
GB201805100D0 (en) Treatment of sarcopenic diseases
IL309393A (en) Retinal disorders
SI3458067T1 (sl) Zdravljenje nevroloških obolenj
EP3761982A4 (en) TREATMENT OF DEMYELINIZATION DISEASES
EP4313024A4 (en) Treatment of inflammatory diseases
IL308669A (en) Methods of treating mitochondria-related disorders